Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-2063

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-2063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride showing its molecular configuration including a naphthalene ring, thiophene ring, amine group, and hydrochloride salt.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time between placebo and duloxetine delayed-release capsules. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients relapsing. Two lines depict the treatments: a dashed line for placebo and a solid line for duloxetine delayed-release capsules.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier plot showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line), illustrating relapse rates over approximately 300 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line chart showing percentage of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. The graph compares four groups: DUL 60mg BID, DUL 60mg QD, DUL 20mg QD, and Placebo, each represented by different markers. The data illustrate the relationship between pain improvement percentage and patient improvement rates for these treatments.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: DUL 60mg BID, DUL 60mg QD, and Placebo. The y-axis shows patients improved in percentage from 0 to 100, and the x-axis shows percent improvement from 0 to 100.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0% to 100%. The graph includes three curves representing two Duloxetine dosing regimens and placebo, illustrating comparative patient improvement over different pain improvement thresholds.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, with the x-axis representing percent improvement in pain and the y-axis representing percentage of patients improved.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine (DUL) 60/120 mg once daily treatment groups. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine shows a higher percentage of patient improvement across most percent improvement intervals compared to placebo.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Duloxetine 60 mg once daily to placebo, with Duloxetine showing higher patient improvement percentages across most improvement levels.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline. It shows two data series: one for placebo and one for Duloxetine (60/120 mg once daily). The graph illustrates that higher percentages of patients improved at varying levels of pain improvement with Duloxetine compared to placebo.*

FDA Label Image

Label (Lbl636292063)

Label for Duloxetine Delayed Release Capsules, USP 40 mg oral capsules, by Bryant Ranch Prepack. The label includes dosage strength (40 mg), NDC 63629-2063-1, manufacturer BRP Pharmaceuticals, and package size of 30 capsules. Storage instructions and safety warnings are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.